Expert Interview
A Look at the Phase 1 Data from Kelonia’s inMMyCAR study Evaluating KLN-1010, an Investigational in vivo BCMA-Directed CAR-T therapy in Patients with Relapsed/refractory Multiple Myeloma
Ticker(s): KELONIA THERAPEUTICS, LLY, BMY, JNJInstitution: Washington University St. Louis
- Professor Department of Medicine Oncology Division Bone Marrow Transplantation & Leukemia at WUSTL
- Currently treats ~300 patients with multiple myeloma, 25 patients with AML, 10 patients with CMML, and ~15 patients per month with AL Amyloidosis.
- Clinical research focus on strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
How are you currently sequencing BCMA-directed therapies in relapsed/refractory multiple myeloma, and where do you see the largest unmet needs?
Added By: sara_adminWhat is your interpretation of the early Phase 1 inMMyCAR data for KLN-1010, particularly around safety, response activity, and feasibility of an in vivo CAR-T approach?
Added By: sara_adminHow do you view the potential advantages and limitations of in vivo CAR-T compared with currently approved ex vivo CAR-T therapies such as ide-cel or cilta-cel?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
